1.
Bersanelli
M
,
Buti
S
,
Rizzo
M
.
The need for new algorithms of treatment sequencing in clear-cell metastatic renal cell carcinoma
.
Expert Rev Anticancer Ther
.
2021 Apr
;
21
(
4
):
401
12
. .
2.
Procopio
G
,
Nichetti
F
,
Verzoni
E
.
Pembrolizumab plus axitinib: another step ahead in advanced renal cell carcinoma
.
Lancet Oncol
.
2020 Dec
;
21
(
12
):
1538
9
. .
3.
McDermott
DF
,
Huseni
MA
,
Atkins
MB
,
Motzer
RJ
,
Rini
BI
,
Escudier
B
,
Clinical activity and molecular correlates of response to atezolizumab alone or in combination with bevacizumab versus sunitinib in renal cell carcinoma
.
Nat Med
.
2018
;
24
(
6
):
749
57
. .
4.
Powles
T
,
Plimack
ER
,
Soulières
D
,
Waddell
T
,
Stus
V
,
Gafanov
R
,
Pembrolizumab plus axitinib versus sunitinib monotherapy as first-line treatment of advanced renal cell carcinoma [KEYNOTE-426]: extended follow-up from a randomised, open-label, phase 3 trial
.
Lancet Oncol
.
2020 Dec
;
21
(
12
):
1563
73
.
5.
Choueiri
TK
,
Powles
T
,
Burotto
M
,
Escudier
B
,
Bourlon
MT
,
Zurawski
B
,
Nivolumab plus cabozantinib versus sunitinib for advanced renal-cell carcinoma
.
N Engl J Med
.
2021 Mar
;
384
(
9
):
829
41
. .
6.
Motzer
RJ
,
Hutson
TE
,
Cella
D
,
Reeves
J
,
Hawkins
R
,
Guo
J
,
Pazopanib versus sunitinib in metastatic renal-cell carcinoma
.
N Engl J Med
.
2013
;
369
(
8
):
722
31
. .
7.
Motzer
RJ
,
Hutson
TE
,
Tomczak
P
,
Michaelson
MD
,
Bukowski
RM
,
Rixe
O
,
Sunitinib versus interferon alfa in metastatic renal-cell carcinoma
.
N Engl J Med
.
2007 Jan
;
356
(
2
):
115
24
. .
8.
Rini
BI
,
Dorff
TB
,
Elson
P
,
Rodriguez
CS
,
Shepard
D
,
Wood
L
,
Active surveillance in metastatic renal-cell carcinoma: a prospective, phase 2 trial
.
Lancet Oncol
.
2016 Sep
;
17
(
9
):
1317
24
. .
9.
Rini
BI
,
Plimack
ER
,
Stus
V
,
Waddell
T
,
Gafanov
R
,
Pouliot
F
,
Pembrolizumab [pembro] plus axitinib [axi] versus sunitinib as first-line therapy for advanced clear cell renal cell carcinoma [ccRCC]: Results from 42-month follow-up of KEYNOTE-426
.
J Clin Oncol
.
2021
;
39
(
Suppl 15
):
4500
. .
10.
Motzer
R
,
Alekseev
B
,
Rha
SY
,
Porta
C
,
Eto
M
,
Powles
T
,
Lenvatinib plus pembrolizumab or everolimus for advanced renal cell carcinoma
.
N Engl J Med
.
2021
;
384
(
14
):
1289
300
. .
11.
Graham
J
,
Heng
DYC
,
Brugarolas
J
,
Vaishampayan
U
.
Personalized management of advanced kidney cancer
.
Am Soc Clin Oncol Educ Book
.
2018
;
38
(
38
):
330
41
. .
12.
Rebuzzi
SE
,
Signori
A
,
Banna
GL
,
Maruzzo
M
,
De Giorgi
U
,
Pedrazzoli
P
,
Inflammatory indices and clinical factors in metastatic renal cell carcinoma patients treated with nivolumab: the development of a novel prognostic score [Meet-URO 15 study]
.
Ther Adv Med Oncol
.
2021
;
13
:
175883592110196
. .
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the...
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.